(Reuters) - Allergan Plc posted a smaller second-quarter loss on Thursday due to demand for the company's Botox anti-wrinkle treatment.
The company reported net loss attributable to ordinary shareholder's of $472.5 million, or $1.39 per share, in the second quarter ended June 30, compared with a loss of $795.5 million, or $2.37 per share, a year ago.
Revenue rose 2.9 percent to $4.12 billion.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)